As covered by Fairfax Times, Novo Nordisk has reported encouraging long-term findings for its investigational hemophilia A therapy denecimig (Mim8), with interim results from the Phase 3 FRONTIER4 extension study…
As reported on BioSpace, BridgeBio Pharma has reported new findings suggesting that its transthyretin (TTR) stabilizer, Attruby (acoramidis), may help preserve kidney function in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM),…
New research from the 2026 American Society of Clinical Oncology (ASCO) annual meeting, and presented on Cure Today, highlights an encouraging new treatment on the horizon for advanced non-small cell…
What Happened? The healthcare company Grifols announced in a recent press release that it has enrolled and dosed the very first patient in a new Phase 3 clinical trial called…
Early Clinical Results Highlight Potential New Treatment Strategy As reported on STAT News, a novel investigational drug combination developed through a collaboration between Tango Therapeutics and Revolution Medicines has demonstrated…
As reported by PharmaBiz, Eli Lilly and Company has announced positive findings from its Phase 3 BRUIN CLL-322 trial evaluating pirtobrutinib (Jaypirca), a next-generation non-covalent Bruton tyrosine kinase (BTK) inhibitor,…
As reported on PharmaBiz, Sumitomo Pharma America (SMPA) presented new clinical and translational data spanning myelofibrosis (MF) and acute leukemia programs at the 2026 European Hematology Association Congress in Stockholm…
As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…
In a recent statement, CONNECTA Therapeutics, a biotechnology company focused on disorders of the central nervous system, has announced the start of its Phase IIa clinical trial for CTH120, a…
As reported on Medscape, global phase 3 clinical trial suggests that veligrotug, an investigational monoclonal antibody targeting the insulin-like growth factor‑1 receptor (IGF‑1R), may offer fast and lasting improvement for…
As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…
As reported on MedCity News, the U.S. Food and Drug Administration (FDA) has issued draft guidance encouraging the thoughtful use of Bayesian statistical approaches in clinical trials, marking a notable…
As reported on Becker's Hospital Review, the U.S. Food and Drug Administration’s launch of a real-time clinical trial model marks a notable shift in how oncology research is conducted and…
As reported on Business Wire, Onchilles Pharma has announced the first patient dosing in a Phase 1/2 clinical trial evaluating its investigational therapy, N17350, in individuals with advanced solid tumors.…
As reported on PharmaBiz, Omnix Medical has reached a key clinical milestone with the initiation of patient dosing in a phase II study of its lead antimicrobial candidate, OMN6. The…
As reported on STAT News, a novel combination of investigational therapies from Tango Therapeutics and Revolution Medicines is generating cautious optimism after demonstrating notable tumor responses in an early-stage clinical…
Merck and Gilead Sciences reported contrasting late-stage outcomes on Monday, pairing a promising advance in HIV treatment with the discontinuation of a high-profile lung cancer trial after underwhelming survival results.…
As reported in BioPharmaDive, the U.S. Food and Drug Administration (FDA) has postponed its decision on camizestrant, an experimental oral therapy for breast cancer being developed by AstraZeneca, following a…
Editor's Note: This article was submitted to us by Regina Portnoy. A clinical trial may be remembered for a breakthrough treatment, a new therapy, or a headline-making discovery. But its…
As reported on PharmaBiz, Infex Therapeutics has announced encouraging results from a phase IIa clinical study of RESP‑X, an investigational monoclonal antibody being developed for patients with non‑cystic fibrosis bronchiectasis…
As reported on PharmaBiz, new findings from the phase 2 ElevAATe trial suggest that the investigational agent efdoralprin alfa may represent a meaningful advance in the treatment of alpha-1 antitrypsin…
As reported on Beckers Hospital Review, the U.S. Food and Drug Administration has authorized ensitrelvir (brand name Xocova) as the first oral antiviral indicated for post-exposure prophylaxis of COVID-19 in…
As reported on BioSpace, the U.S. Food and Drug Administration (FDA) has granted priority review to BridgeBio Pharma’s investigational therapy, BBP-418, marking a key regulatory milestone for a condition that…
Editor's Note: This article was originally written and shared with us by Caleigh Haber. This day hits really close to home for me. I was born with Cystic Fibrosis in…
As reported by PharmaBiz, Japan’s Ministry of Health, Labour and Welfare (MHLW) has broadened the approved use of GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, to cover adults aged 18–49…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
